Aubagio® delays onset of clinically definite MS, study
Aubagio® delays onset of clinically definite MS, study
Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1415 Views
-
Last post by NHE
-
- 0 Replies
- 768 Views
-
Last post by NHE
-
- 0 Replies
- 2169 Views
-
Last post by frodo
-
- 0 Replies
- 1049 Views
-
Last post by NHE
-
- 1 Replies
- 981 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1268 Views
-
Last post by frodo
-
- 0 Replies
- 1459 Views
-
Last post by NHE
-
- 0 Replies
- 1993 Views
-
Last post by vesta
-
- 0 Replies
- 1534 Views
-
Last post by frodo